Dyskinesia - Pipeline Review, H2 2017

Date: September 12, 2017
Pages: 147
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: DA5E756AD75EN
Leaflet:

Download PDF Leaflet

Dyskinesia - Pipeline Review, H2 2017
Dyskinesia - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H2 2017, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Dyskinesia - Overview
Dyskinesia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Dyskinesia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dyskinesia - Companies Involved in Therapeutics Development
Adamas Pharmaceuticals Inc
Addex Therapeutics Ltd
Advicenne SA
Avanir Pharmaceuticals Inc
Bionomics Ltd
Catalyst Biosciences Inc
Cavion LLC
Clevexel Pharma SAS
EpiVax Inc
Heptares Therapeutics Ltd
Ipsen SA
Merz Pharma GmbH & Co KgaA
Neurim Pharmaceuticals Ltd
Neurocrine Biosciences Inc
Neurolixis Inc
Osmotica Pharmaceutical Corp
Phenomenome Discoveries Inc
Sage Therapeutics Inc
SciFluor Life Sciences LLC
SOM Biotech SL
Synchroneuron Inc
Dyskinesia - Drug Profiles
(dextromethorphan + quinidine sulfate) - Drug Profile
A-2M13677 - Drug Profile
abobotulinumtoxinA - Drug Profile
acamprosate calcium SR - Drug Profile
amantadine hydrochloride ER - Drug Profile
amantadine hydrochloride ER - Drug Profile
AT-127 - Drug Profile
AT-326 - Drug Profile
AT-403 - Drug Profile
befiradol - Drug Profile
brexanolone - Drug Profile
CVXL-0107 - Drug Profile
CX-8998 - Drug Profile
cycloserine - Drug Profile
dipraglurant IR - Drug Profile
Drug for Dyskinesia - Drug Profile
Drug for Tardive Dyskinesia - Drug Profile
Drugs for Dyskinesia - Drug Profile
Gene Therapy to Inhibit TRH for Dyskinesia - Drug Profile
HTL-14242 - Drug Profile
incobotulinumtoxin A - Drug Profile
IRL-790 - Drug Profile
JM-010 - Drug Profile
MLR-1019 - Drug Profile
NBI-640756 - Drug Profile
Neu-120 - Drug Profile
Neu-240 - Drug Profile
onabotulinumtoxinA - Drug Profile
PCT-3010 - Drug Profile
PPI-1011 - Drug Profile
RNAi Gene Therapy to Inhibit NURR1 for Dyskinesia - Drug Profile
SAGE-217 - Drug Profile
SK-609 - Drug Profile
Small Molecule for Dyskinesia - Drug Profile
Small Molecule for Dyskinesia - Drug Profile
Small Molecules for Neurodegenerative Disease - Drug Profile
Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile
Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile
SOM-3355 - Drug Profile
TC-8831 - Drug Profile
tetrabenazine - Drug Profile
valbenazine tosylate - Drug Profile
Dyskinesia - Dormant Projects
Dyskinesia - Discontinued Products
Dyskinesia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Dyskinesia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Dyskinesia - Pipeline by Adamas Pharmaceuticals Inc, H2 2017
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2017
Dyskinesia - Pipeline by Advicenne SA, H2 2017
Dyskinesia - Pipeline by Avanir Pharmaceuticals Inc, H2 2017
Dyskinesia - Pipeline by Bionomics Ltd, H2 2017
Dyskinesia - Pipeline by Catalyst Biosciences Inc, H2 2017
Dyskinesia - Pipeline by Cavion LLC, H2 2017
Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2017
Dyskinesia - Pipeline by EpiVax Inc, H2 2017
Dyskinesia - Pipeline by Heptares Therapeutics Ltd, H2 2017
Dyskinesia - Pipeline by Ipsen SA, H2 2017
Dyskinesia - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017
Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
Dyskinesia - Pipeline by Neurocrine Biosciences Inc, H2 2017
Dyskinesia - Pipeline by Neurolixis Inc, H2 2017
Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp, H2 2017
Dyskinesia - Pipeline by Phenomenome Discoveries Inc, H2 2017
Dyskinesia - Pipeline by Sage Therapeutics Inc, H2 2017
Dyskinesia - Pipeline by SciFluor Life Sciences LLC, H2 2017
Dyskinesia - Pipeline by SOM Biotech SL, H2 2017
Dyskinesia - Pipeline by Synchroneuron Inc, H2 2017
Dyskinesia - Dormant Projects, H2 2017
Dyskinesia - Dormant Projects, H2 2017 (Contd..1), H2 2017
Dyskinesia - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Dyskinesia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Adamas Pharmaceuticals Inc
Addex Therapeutics Ltd
Advicenne SA
Avanir Pharmaceuticals Inc
Bionomics Ltd
Catalyst Biosciences Inc
Cavion LLC
Clevexel Pharma SAS
EpiVax Inc
Heptares Therapeutics Ltd
Ipsen SA
Merz Pharma GmbH & Co KgaA
Neurim Pharmaceuticals Ltd
Neurocrine Biosciences Inc
Neurolixis Inc
Osmotica Pharmaceutical Corp
Phenomenome Discoveries Inc
Sage Therapeutics Inc
SciFluor Life Sciences LLC
SOM Biotech SL
Synchroneuron Inc
Skip to top


Tardive Dyskinesia - Pipeline Review, H2 2015 US$ 2,000.00 Jul, 2015 · 56 pages

Ask Your Question

Dyskinesia - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: